Status:
COMPLETED
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborating Sponsors:
Centro de Investigación Biomédica en Red de Salud Mental
Instituto de Investigación Marqués de Valdecilla
Conditions:
Schizophrenia
Schizophrenia Relapse
Eligibility:
All Genders
15-60 years
Phase:
NA
Brief Summary
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-...
Eligibility Criteria
Inclusion
- Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the University Hospital Marqués de Valdecilla (Santander, Spain).
- A minimum of 18 months on antipsychotic treatment.
- Meeting clinical remission criteria for at least the 12 months prior to inclusion.
- Meeting the functional recovery criteria for at least the 6 months prior to inclusion.
- Stabilized at the lowest effective doses for at least the 3 months prior to inclusion.
Exclusion
- Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for drug dependence.
- Meeting DSM-IV criteria for mental retardation.
- Having a history of neurological disease or head injury.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT02220504
Start Date
July 1 2004
End Date
July 1 2014
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Marques de Valdecilla
Santander, Cantabria, Spain, 39008